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Galectin-1 and galectin-3 are the most ubiquitously expressed members of the galectin family and more importantly, these two molecules are
shown to have opposite effects on pro-inflammatory responses and/or apoptosis depending on the cell type. Herein, we demonstrate for the first time
that galectin-3 induces mast cell apoptosis. Mast cells expressed substantial levels of galectin-3 and galectin-1 and to a lesser extent the receptor for
advanced glycation end products (RAGE) on their surfaces. Treatment of cells with galectin-3 at concentrations of≥100 nM for 18–44 h resulted in
cell death by apoptosis. Galectin-3-induced apoptosis was completely prevented by lactose, neutralizing antibody to RAGE, and the caspase-3
inhibitor z-DEVD-fmk. Galectin-3-induced apoptosis was also completely abolished by dithiothreitol and superoxide dismutase, but not inhibited by
catalase. Moreover, galectin-3 but not galectin-1 induced the release of superoxide, which was blocked by lactose, anti-RAGE, and dithiothreitol.
Finally, galectin-3-induced apoptosis was blocked by bongkrekic acid, an antagonist of the mitochondrial permeability transition pore (PTP), while
atractyloside, an agonist of the PTP, greatly facilitated galectin-1-induced apoptosis. These data suggest that galectin-3 induces oxidative stress, PTP
opening, and the caspase-dependent death pathway by binding to putative surface receptors including RAGE via the carbohydrate recognition
domain.
© 2008 Elsevier B.V. All rights reserved.Keywords: Mast cell; Galectin-3; Galectin-1; Reactive oxygen species; Apoptosis; Mitochondria1. Introduction
Galectins are members of animal lectins that bind β-galacto-
sides through evolutionary conserved sequence elements of the
carbohydrate recognition-binding domain (CRD) [1]. To date
more than ten members of this family have been identified,
cloned, and classified into three subgroups, based on their struc-
ture and number of CRDs: (i) Prototype (galectin-1,-2,-5,-7,-10,-
11,-13, and -14); (ii) Chimera type (galectin-3); (iii) Tandem
repeat type (galectin-6,-8,-9, and -12) [2]. It has been suggested
that these multivalent members of the galectin family might
play differential roles in various biological responses [3]. The
galectins positively and negatively regulate cell death [4–6].⁎ Corresponding author. Tel.:+81 3 3972 8111; fax: +81 3 3972 8227.
E-mail address: ysuzuki@med.nihon-u.ac.jp (Y. Suzuki).
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doi:10.1016/j.bbamcr.2008.01.025Galectin-1,-2,-3,-7,-8,-9, and -12 can regulate cell death ei-
ther inside or outside the cell [7–12]. Because galectins are
carbohydrate-binding proteins, galectins that act extracellularly
to induce cell death do so by binding specific glycoconjugates in
a saccharide-dependent manner.
Galectin-1 and galectin-3 are themost ubiquitously expressed
members of the galectin family. In some tissues, only galectin-1
or galectin-3 is expressed, whereas in many immune cells and
tissues, galectin-1 and galectin-3 are coexpressed. They include
T cells, B cells, NK cells, macrophages, dendritic cells, endo-
thelial cells, and fibroblasts as well as thymus and lymph nodes
[13–15]. It has been shown that galectin-3 is expressed in
cultured primary mast cells, tissue mast cells, and mast cell lines
[16,17]. An exogenous source of galectin-3 has been shown to
activate mast cells [18,19]. Amore recent study using galectin-3-
deficient mast cells demonstrated that galectin-3 is involved in
mast cell degranulation, IL-4 production, and passive cutaneous
925Y. Suzuki et al. / Biochimica et Biophysica Acta 1783 (2008) 924–934anaphylaxis [20]. However, the role of galectins in mast cell
survival and death is unclear.
Mast cells play a critical role in allergic and inflammatory
reactions as well as innate and acquired immunity [21]. The
binding of multivalent antigens to the IgE-bound high-affinity
IgE receptor (FcɛRI) causes an aggregation of the receptor and
initiates transmembrane signal transduction. This results in the
secretion of preformed or newly synthesized mediators and the
production of cytokines with pro-inflammatory and immuno-
modulatory properties [22,23]. By analogy to other immune
cells, mast cells might express both galectin-3 and galectin-1.
However, there are few reports on the expression of galectins
other than galectin-3 in mast cells. Therefore, we sought to
analyze the expression of galectin-3 and galectin-1, paying
close attention to the potential roles of these two galectins in the
regulation of mast cell survival. Herein, we demonstrate that
mast cells express both galectin-3 and galectin-1 and that
extracellular galectin-3 can exhibit strong pro-apoptotic activity
through inducing oxidative stress and mitochondrial perme-
ability transition.
2. Materials and methods
2.1. Materials
Recombinant mouse galectin-1 and galectin-3, and the neutralizing
antibodies to galectin-1 and galectin-3 were obtained from R&D Systems
(Minneapolis, MN, USA). Thapsigargin (TG), dithiothreitol (DTT), and
superoxide dismutase (SOD), and atractyloside were obtained from Sigma
(St. Louis, MO, USA). Both TG and atractyloside were dissolved in dimethyl
sulfoxide (DMSO) and diluted with Hank's balanced salt solution (HBSS) to a
final concentration of b0.1% before use. DMSO, at a concentration of 0.1%
had no effects on its own throughout the present study. Bongkrekic acid
dissolved in water was obtained from BioMol (Plymouth Meeting, PA, USA).
The neutralizing antibody to RAGE was purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). Fluo3-acetoxyl-methyl ester
(Fluo3/AM) and z-DEVD-fmk were purchased from Dojindo Laboratories
(Kumamoto, Japan) and Calbiochem (San Diego, CA), respectively. Anti-
2,4,6-trinitrophenyl (anti-TNP) IgE monoclonal antibody (clone IgE-3) was
purchased from BD PharMingen Japan (Tokyo, Japan). TNP-bovine serum
albumin (BSA) conjugate (25 molecules of TNP coupled to 1 molecule of
BSA) was purchased from Cosmo Bio Co. (Tokyo, Japan). All other chemicals
were of analytical grade.
2.2. RBL-2H3 cells
The RBL-2H3 cells obtained from the National Institute of Health Sciences
(Japanese Collection of Research Biosources [JCRB]; cell number JCRB0023)
were grown in DMEM (Sigma) supplemented with 10% FBS (SAFC
Biosciences, Tokyo, Japan) in a 5% CO2-containing atmosphere. The cells
were harvested by incubating them in HBSS containing 1 mM ethylenediamine
tetraacetate (EDTA) and 0.25% trypsin for 5 min at 37 °C. For IgE sensitization,
the cells suspended in complete DMEM were plated on a 100-mm culture dish
(1×106/ml) or in a 6-well plate (1×106/well) and incubated with anti-TNP IgE
(0.1 μg) at 37 °C overnight. IgE-sensitized cells were washed with PBS and
suspended in HBSS.
2.3. BMMCs
Bone marrow-derived mast cells (BMMCs) were prepared from femurs of 4-
to 8-week-old C3HeBFeJ mice, as described previously [24]. All animal
experiments were performed according to Nihon University guidelines. The cells
were cultured in RPMI 1640 medium (Sigma) supplemented with 10% FBS,100 U/ml penicillin, and streptomycin (Invitrogen Corp., Carlsbad, CA, USA),
5×10−5 M mercaptoethanol (2-ME; Wako Pure Chemicals, Osaka, Japan),
100 μg/ml sodium pyruvate (Invitrogen), 1%MEM (minimal essential medium)
nonessential amino acid solution (Invitrogen), and 5 ng/ml recombinant IL-3
(Pepro Tech Inc., Rocky Hill, NJ, USA) in a 5% CO2-containing atmosphere at
37 °C. After 4 to 6 weeks of culture, the cells were stained for cell surface
expression of FcɛRI, and BMMCs were used for experiments after 4 to 8 weeks
of culture (N95% mast cells).
2.4. Surface expression of galectin-1 and galectin-3
Expression of galectin-1 and galectin-3 on the cell surface was determined
by flow cytometry. RBL-2H3 cells or BMMCs (5×105/20 μl) were incubated
with the anti-galectin-1 or anti-galectin-3 antibody for 30 min at 4 °C. The cells
were pelleted down by centrifugation and resuspended in PBS. The cells were
incubated with FITC-conjugated anti-goat IgG (Santa Cruz) for 30 min at 4 °C.
The expression of galectin-1 and galectin-3 on these cells was evaluated in a
FACSCalibur (Becton-Dickinson, San Jose, CA, USA) and analyzed using
CellQuest software (Becton-Dickinson).
2.5. Evaluation of cell death
Apoptotic cell death and overall cell death were evaluated by double staining
with fluorescein isothiocyanate (FITC)-conjugated annexin V and propidium
iodide (PI). Briefly, after the cells adhered in a 24-well plate (5×105/200 μl/well)
were treated with inhibitor tested in 10% FBS/DMEM and then stimulated for
18–22 h, phosphatidylserine translocated from the inner to the outer leaflet of the
plasma membrane was detected by annexin V staining using a commercially
available kit (Annexin V-FITC Apoptosis Detection Kit I, BD Pharmingen, San
Diego, CA, USA), according to the manufacturer's instructions. By double
staining cells with annexinV-FITC and propidium iodide (PI), the subsets of cells
that were annexin V-positive, PI-negative (apoptotic) and annexin V-positive,
and PI-positive (necrotic and/or advanced apoptotic cells) were determined.
Double negative cells were considered to be living cells. These stained cells were
evaluated in a FACSCalliber and analyzed using CellQuest software (Becton-
Dickinson).
2.6. Cytochrome c release assay
Cells plated in a 6-well plate (3×106/well) were washed and treated with
100 nM each of galectin-1 or galectin-3 in DMEM containing 10% FBS for 18 h.
To assess cytochrome c content in the mitochondria, the cells were fractionated
into mitochondria and cytosolic fractions by differential centrifugation using a
mitochondria isolation kit (Pierce Biotechnology, Rockford, IL, USA), and the
mitochondrial fraction was lysed with 1% Triton X-100. Because preliminary
experiments showed that in the case of RBL-2H3 cells, a considerable amount of
cytochrome c was released into medium, we collected the cultured medium
and the cytosolic fraction together and referred to as an extramitochondrial
fraction. Cytochrome c contents in intra- and extramitochondrial fractions were
determined using a commercially available solid phase sandwich ELISA kit
(R&D Systems, Minneapolis, MN, USA), according to the manufacturer's
protocol.
2.7. Measurement of caspase-3/7 activation
Cells plated in a 6-well plate (3×106/well) were washed and treated with
100 nM each of galectin-1 or galectin-3 in DMEM containing 10% FBS for 18 h.
Caspase-3/7 activation and changes in mitochondrial membrane potential were
determined using the Dual Sensor: MitoCasp (Cell Technology Inc. Mountain
View, CA, USA), according to the manufacturer's protocol. Stained cells were
evaluated in a FACSCaliber and analyzed using CellQuest software.
2.8. Degranulation assay
Degranulation was determined by β-hexosaminidase release. RBL-2H3 cells
were stimulated at 37 °C for 30 min, and β-hexosaminidase activity in
supernatants was determined spectrophotometrically as previously described
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glucosaminide (in 0.4 M citrate and 0.2 M phosphate buffer, pH 4.5; ICN
Biochemicals, Eschwege, Germany) were added to each well of a 96-well plate,
and color was developed for 30min at 37 °C. Enzyme reaction was terminated by
adding 200 μl of 0.2 M glycine-NaOH, pH 10.7. The absorbance at 415 nm was
measured in a microplate reader (Bio-Rad 550 Nippon Bio-Rad Laboratories,
Osaka, Japan). Cells were lysed with 0.1% Triton X-100, and the extract was
analyzed for the β-hexosaminidase activity (total). The β-hexosaminidase
activity in unstimulated cells (spontaneous release,b5% of total enzyme activity)
was subtracted from the enzyme activity (test). The percentage of β-
hexosaminidase released into the supernatant was calculated using the following
formula: release (%)=(test− spontaneous) / (total−spontaneous)×100.
2.9. Extracellular release of O2
U−
The extracellular release of O2
U− was measured by SOD-inhibitable
cytochrome c reduction assay as previously described [25] with minor
modifications. Briefly, RBL-2H3 cells (1×106/ml) were added with apocynin
and then immediately stimulated with antigen, and 20 μM cytochrome c was
added. The reduction of absorbance at 540 nm (ΔOD540) was measured
immediately in a microplate reader (Bio-Rad 550). To measure SOD-
dependent response, SOD was added to the reaction mixture in separateFig. 1. Mast cells express galectin-3 and galectin-1 on their surfaces. (A, B) For ev
2H3 cells (A) or BMMCs (B) in PBS were stained with anti-galectin-3 or anti-gal
cytometer. The bold line represents specific staining and the solid line represents t
fractionated into cytosolic, membrane/particulate, nuclear, and cytoskeletal fractio
SDS-PAGE using a 10% separation gel under reducing conditions, and probed
experiments.samples at a final concentration of 100 U/ml, and the reduction of absorbance
at 540 nm (ΔOD540 [SOD]) was measured in the same way. The data are
shown as SOD-inhibitable cytochrome c reduction, corresponding to
ΔOD540−ΔOD540 [SOD].
2.10. Statistical analysis
The Student's t-test was performed to determine statistical significance
among the experimental groups; pb0.05 was considered significant.
3. Results
3.1. Mast cells express galectin-3 and galectin-1 on their surfaces
Galectin-3 and galectin-1 are the most ubiquitously ex-
pressed members of the galectin family and more importantly,
these two galectins are shown to have opposite effects on pro-
inflammatory responses and/or apoptosis depending on cell
type. To understand the roles of galectins in mast cell biology,
we first evaluated the expression of galectin-1 and galectin-3 inaluation of the expression of galectin-3 and galectin-1 on their surfaces, RBL-
ectin-1 antibody, and the expression of each galectin was evaluated in a flow
he non-stained control. (C, D) RBL-2H3 cells or BMMCs (1×107 each) were
ns as described in Materials and methods, and each fraction was subjected to
with anti-galectin-3. The data are the representative of three independent
927Y. Suzuki et al. / Biochimica et Biophysica Acta 1783 (2008) 924–934mast cells. RBL-2H3 cells (a tumor mast cell line) and
BMMCs (primary cultured mast cells) were analyzed for the
expression of galectin-3 on their surfaces. Staining by
polyclonal antibody raised against the recombinant mouseFig. 2. Galectin-3 but not galectin-1 induces mast cell apoptosis. (A) RBL-2H3 cells
30 nM (b), 100 nM (c), or 300 nM galectin-3 (Gal-3) (d) and 30 nM (e), 100 nM (f)
Cells were stained with FITC-conjugated annexin Vand PI, and analyzed in a flow c
grown in a 24-well plate (5×105/200 μl) were incubated with 0 nM (vehicle, a), 100 n
was analyzed as described above. The data are representative of at least three indepgalectin-3 showed that galectin-3 was expressed substantially
on the surfaces of RBL-2H3 cells and BMMCs (Fig. 1A and
B). Basically the same results were obtained with galectin-1
(Fig. 1A and B).grown in a 24-well plate (5×105/200 μl) were incubated with 0 nM (vehicle, a),
or 300 nM galectin-1 (Gal-1) (g) for 18 h at 37 °C, and the cells were harvested.
ytometer. Double negative cells were considered as living cells. (B, C) BMMCs
M Gal-3 (b) or 100 nM Gal-1 (c) for 24 h (B) or 48 h (C) at 37 °C and cell death
endent experiments.
Fig. 3. Galectin-3 activates mast cells to enter apoptosis without degranulation. (A) RBL-2H3 cells grown in a 24-well plate (5x105/200 µl) were incubated with 100 nM
each of galectin-1 or galectin-3 or 30 ng/ml TNP-BSA for 30 min at 37 °C, and thenβ-hexosaminidase activity in supernatants was determined spectrophotometrically. (B)
RBL-2H3 cells grown in a 24-well plate (2×105/well) were sensitized with monoclonal anti-TNP IgE antibody overnight. After washing, the IgE-sensitized cells were
incubated with 30 ng/ml TNP-BSA for 18 h at 37 °C, and the cells were harvested. Cells were stained with FITC-conjugated annexin V and PI, and analyzed in a flow
cytometer. (C) RBL-2H3 cells (3×106/ml) were stimulated with 100 nM each of galectin-1 or galectin-3 for 18 h at 37 °C. Then, the cells were fractionated into
mitochondrial and cytosolic fractions by differential centrifugation, and the cytochrome c content in each fractionwas determined using anELISA kit. The data represent the
mean±SEM of four independent experiments. Statistical significance versus vehicle stimulation in each fraction was determined using an unpaired Student's t-test.
⁎⁎⁎pb0.001. (D, E) RBL-2H3 cells plated in a 6-well plate (3×106/well) were washed and treated with 100 nM each of galectin-1 or galectin-3 in DMEM containing 10%
FBS for 18 h. Caspase-3/7 activation and changes inmitochondrial membrane potential were determined as described inMaterials andmethods. The data represent themean
±SEM of four independent experiments. Statistical significance was determined using an unpaired Student's t-test. ⁎⁎pb0.01.
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Fig. 4. Galectin-3 elicits the pro-apoptotic effect through binding to a putative surface receptor via the CRD domain. RBL-2H3 cells grown in a 24-well plate (5×105/200 μl)
were incubatedwith 100 nMGal-3 (b–e) or 1μMthapsigargin (TG) (f–i) for 18 h at 37 °C in the presence of 10mMlactose (LAC) (c,g), 1μg/ml anti-galectin-3 (α-gal-3) (d,h)
or anti-galectin-1 (α-gal-1) (e,i), and cell death was analyzed by annexin V/PI double staining. The data are representative of at least three independent experiments.
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Next, we examined whether galectin-1 or galectin-3 could
trigger mast cell death. RBL-2H3 cells were exposed to varying
concentrations (30–300 nM) of galectin-1 or galectin-3 for 24–
48 h, and cell death was determined by staining by annexin V
and PI. As shown in Fig. 2A, treatment with galectin-3 for 24 h
resulted in apoptosis, as evidenced by the appearance of annexinFig. 5. RAGE mediates the pro-apoptotic activity of galectin-3. (A) RBL-2H3 cells o
RAGEwas evaluated in a flow cytometer. The bold line represents specific staining an
24-well plate (5×105/200 μl) were incubated with 100 nMGal-3 (b,c) or 1 μMTG (d,e
for 18 h at 37 °C, and cell death was analyzed by annexin V/PI double staining. TheV-positive cells, though the effect was smaller than that of TG,
whichwas used as a positive control. Galectin-3 showed the effect
in a concentration-dependent manner with a minimal effective
dose of 30 nM (annexin V-positive population in control cells and
100 nM galectin-3-treated cells was 6.2±1.2% and 40.2±5.5%,
respectively, n=6, pb0.001) (Fig. 2A, panels a–d). The effect
became more evident at 48 h. On the other hand, treatment with
galectin-1 up to 300 nM for 24 h had a minimal effect on the cellr BMMCs in PBS were stained with anti-RAGE antibody, and the expression of
d the solid line represents the non-stained control. (B) RBL-2H3 cells grown in a
) in the absence (b,d) or presence of 1 μg/ml anti-RAGE antibody (α-RAGE) (c,e)
data are representative of at least three independent experiments.
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galectin-3 for 24 h resulted in a considerable apoptosis of BMMCs
(annexin V-positive population in control cells was 21.7±3.6%
and 56.4±4.3%, respectively, n=3, pb0.01) and this effect be-
came more evident during the next 24 h (Fig. 2B and C, panel b),
while galectin-1 had no significant effect on cell survival for up to
48 h (Fig. 2B and C, panel c).
It has been shown that ɛBP, which is identical to galectin-3,
can evoke mast cell degranulation [18,19] and that mast cell
degranulation results in phosphatidylserine externalization in the
absence of apoptosis [26]. We therefore examined whether
galectin-3 affected mast cell degranulation under the experi-
mental conditions. As shown in Fig. 3A, galectin-3 had no
significant effect on β-hexosaminidase release at concentrations
that effectively induce apoptosis. On the other hand, FcɛRI
stimulation had a minimal effect on phosphatidylserine exter-
nalization, as determined by annexin V staining (Fig. 3B),
although it evoked substantial degranulation (Fig. 3A). These
data exclude the possibility that the phosphatidylserine externa-Fig. 6. ROS and thiol oxidation mediate the pro-apoptotic activity of galectin-3. (A
100 nM Gal-3 (b–e) or 1 μM TG (f–i) in the absence (b,f) or presence of 10 U/ml SO
death was analyzed by annexin V/PI double staining. The data are representative of
stimulated with 100 nM Gal-3 (B) or Gal-1 (C) in the absence or presence of 100 μM
extracellular release of O2
U− was measured by monitoring cytochrome c reduction (t
representative of three independent experiments.lization is merely due to degranulation. To confirm the ability of
galectin-3 to evoke apoptotic cell death, we determined the
collapse of mitochondrial membrane potential, the release of the
apoptogenic protein cytochrome c from the mitochondria, and
the downstream caspase activation. The results showed that
galectin-3 but not galectin-1 evoked mitochondrial cytochrome
c release and substantial caspase-3/7 activation in concomitant
with reduced mitochondrial membrane potential (Fig. 3C, D
and E). Collectively, these data demonstrate that galectin-3
activates mast cells to enter the mitochondrial apoptosis without
degranulation.
3.3. RAGE mediates galectin-3-induced apoptosis in a
carbohydrate-dependent manner
Because galectins are carbohydrate-binding proteins that
bind to specific glycoproteins in a carbohydrate-dependent
manner, we next determined whether the carbohydrate interac-
tion mediated the effect of galectin-3. The presence of lactose) RBL-2H3 cells grown in a 24-well plate (5×105/200 μl) were incubated with
D (c,g), 100 μM DTT (d,h), or 10 U/ml catalase (e,i) for 18 h at 37 °C, and cell
at least three independent experiments. (B, C) RBL-2H3 cells (1×106/ml) were
DTT, 10 mM lactose, 10 U/ml catalase, or 1 μg/ml anti-RAGE antibody, and
he reduction of absorbance at 540 nm) in a microplate reader. The data are the
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effect on TG-induced apoptosis (Fig. 4, panels c and g),
indicating that the β-galactoside-binding site is selectively
involved in triggering apoptosis by galectin-3. Galectin-3-
induced apoptosis was also completely blocked by the anti-
galectin-3 IgG but not by the anti-galectin-1 IgG (Fig. 4, panels d
and e). In contrast, TG-induced apoptosis was affected by
neither antibodies (Fig. 4, panels h and i), indicating the in-
dependence of these two galectins. These results show that
galectin-3 elicits the pro-apoptotic effect through binding to a
putative surface receptor via the CRD domain. Recent studies
have demonstrated that both galectin-3 and RAGE serve as an
AGE receptor [27]. In addition, we have recently found that one
of the AGEs, glycated-albumin induces mast cell apoptosis.
Unexpectedly, the pro-apoptotic activity is blocked not only by
the anti-RAGE IgG but also by the anti-galectin-3 IgG, whereas
the anti-galectin-1 IgG is ineffective (Yoshimaru and Suzuki,
unpublished results). These data suggest the functional coupling
among AGEs, RAGE, and galectin-3. This led us to examine the
possibility that RAGE might act as a galectin-3 receptor. As
shown in Fig. 5A, a small but substantial level of RAGE was
expressed in the surfaces of RBL-2H3 cells and BMMCs. In
addition, galectin-3-induced apoptosis was completely pre-
vented by the anti-RAGE IgG, whereas, TG-induced apoptosisFig. 7. Role of a mitochondrial death pathway in the galectin-3-induced apoptosis.
100 nMGal-3 (A) or Gal-1(B) in the absence (b,e) or presence of 1 μMbongkrekic aci
at 37 °C, and cell death was analyzed by annexin V/PI double staining. In (A) panels a
were obtained in the same experiment. The data are the representative of at least thrwas unaffected (Fig. 5B, panels c and e). These data suggest that
RAGE mediates the pro-apoptotic activity of galectin-3.
3.4. The role of oxidative stress and thiol oxidation in
galectin-3-induced apoptosis
Because ROS are intimately associated with both apoptotic
and non-apoptotic/necrotic cell death, we next elucidated the role
of ROS in the pro-apoptotic activity of galectin-3. RBL-2H3 cells
were exposed to galectin-3 in the absence or presence of exo-
genous ROS-scavenging enzymes and drugs, including SOD,
catalase, and the thiol-reducing agent DTT. As shown in Fig. 6A,
both exogenous SOD and DTT completely blocked galectin-3-
induced apoptosis (panels c and d), while exogenous catalase
had no effect (panel e), indicating that ROS most likely extra-
cellular O2
U− mediates the pro-apoptotic function of galectin-3.
The role of ROS is specific for galectin-3, because these ROS-
modulating agents had no effect on TG-induced apoptosis
(Fig. 6A, panels f–i). We next examined the ability of galectin-
3 or galectin-1 to induce the generation of O2
U−. As shown in
Fig. 6B, galectin-3 stimulated the production and release of O2
U−
into the medium, as evidenced by the SOD-inhibitable reduction
of cytochrome c. The production of O2
U− was seen immediately,
reaching its maximum within few minutes, and keeping the levelRBL-2H3 cells grown in a 24-well plate (5×105/200 μl) were incubated with
d (BKA), 10 μMatractyloside (ATR) or 10 μM z-DEVD-fmk (z-DEVD) for 18 h
–d and e–g were obtained in different experiments. Panels (A, a–d) and (B, a–e)
ee independent experiments.
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by lactose and DTT, while it was partially reduced by catalase and
the anti-RAGE IgG (50% inhibition) (Fig. 6B). Although
galectin-1 provoked substantial production of O2
U−, the effect
was not reduced by lactose, the anti-RAGE IgG, DTT, and
catalase (Fig. 6C), indicating that this oxidative response takes
place independently of RAGE and thiol oxidation. Taken to-
gether, these data show that oxidative stress and thiol oxidation
via RAGE mediate galectin-3-induced apoptosis.
3.5. The role of mitochondria in galectin-3-induced apoptosis
The intrinsic or mitochondrial apoptotic pathway is a major
death pathway, where mitochondria act as central gateway
controllers through the release of a number of mitochondrial
proteins such as cytochrome c and SMAC/Diablo. The critical
step in the mitochondrial pathway is increased permeability of
the mitochondrial outer membrane. The mitochondrial channel,
PTP in the inner membrane has been proposed to be responsible
for the increased permeability of the mitochondrial outer mem-
brane [28,29]. To elucidate the role of PTP in galectin-3-induced
apoptosis, we examined the effect of pharmacological drugs
affecting the PTP open-closed transitions on the apoptosis.
Bongkrekic acid (BKA) can inhibit the adenine nucleotide
translocase (ANT) and stabilizes it on thematrix side, closing the
PTP, while atractyloside (ATR) stabilizes the ANT on the
cytoplasm side, opening the PTP [30,31]. As described above
galectin-3 alone could induce a considerable level of apoptosis,
and this effect was completely abolished by BKA and sig-
nificantly enhanced by ATR (Fig. 7A, panels c and d), indicating
the role of the PTP in galectin-3-induced apoptosis. Galectin-3-
induced apoptosis was also prevented by the caspase-3 inhibitor
z-DEVD-fmk (Fig. 7A, panel g), indicating the role of the
caspase-dependent death pathway. Notably, as mentioned
above, galectin-1 alone had a minimal effect on RBL-2H3 cell
survival. However, galectin-1 caused considerable apoptosis
when used together with ATR, though ATR on its own had a
minimal effect on cell survival (Fig. 7B, panels d and e).
4. Discussion
In the current study we demonstrated that both BMMCs and
RBL-2H3 cells expressed galectin-3 on their surfaces.Moreover,
we demonstrated that these mast cells expressed galectin-1 on
their surfaces as well. Similar levels of galectin-3 and galectin-1
were expressed with similar subcellular distributions except in
the nucleus. Thus, as in many other immune cells, galectin-3 and
galectin-1 appear to be coexpressed in mast cells. Galectin-1 and
galectin-3 are shown to have opposite effects on apoptosis
depending on the cell type [6,32,33]. Therefore, the next inter-
esting question to be addressed is whether these galectins can
modulate mast cell survival. Because galectins are found as
soluble carbohydrate-binding proteins in a spectrum of normal
and tumor cells, we examined the effect of exogenously added
galectin-1 and galectin-3 on mast cell survival. Our data clearly
demonstrate that galectin-3 can induce apoptosis of RBL-2H3
cells and BMMCs, while galectin-1 cannot do so. Galectin-3 atconcentrations of as low as 100 nM induced mast cell apoptosis
significantly, whereas galectin-1 up to 300 nM was ineffective.
Thus, in mast cells extracellular galectin-3 exhibits strong pro-
apoptotic activity, these effects are dependent on its lectin
properties and submicromolar concentrations are effective.
Studies on the physiology of several cell types, mainly
T cells, have suggested the paradigm of “anti-inflammatory”
galectin-1 and “pro-inflammatory” galectin-3 [34]. This theory
may be based on the apparent opposing effects of these two
galectins on chronic and acute inflammatory processes as well
as the survival of cells involved in immune and inflammatory
responses. Galectin-1 has been proposed to be a negative regu-
lator of the immune response [35,36]: Galectin-1 suppresses in
vitro T cell activation, cell growth, and induces T cell apoptosis
[35–37] and ameliorates in vivo the development of chronic
inflammation and inflammatory disorders such as autoimmune
encephalomyelitis, arthritis, hepatitis, and colitis. On the other
hand, galectin-3 appears to be a positive regulator of inflam-
mation. Galectin-3 promotes respiratory burst [38,39], prevents
T cell apoptosis [40] and promotes chemotaxis of macrophages
and monocytes, and induces activation of mast cells as men-
tioned above. On the contrary, consistent with the current study,
exogenously added galectin-3 is demonstrated to induce T cell
apoptosis [41,42]. However, growing evidence indicates that
the same galectin may exert pro- or anti-inflammatory effects as
well as pro- or anti-apoptotic properties, depending on multiple
factors, including the concentration and the target cell tested, the
method of application/overexpression, and the subcellular
localization [6,32,33]. Notably, our preliminary data showed
that there was a considerable variation in the sensitivity to
galectin-3 as well as the localization of galectin-3 in the nucleus
among several RBL-2H3 sublines. This may be related to the
fact that galectin-3 is a putative shuttling protein between the
nuclear and cytoplasm space [43]. There is evidence that in
several cell types including T cells, this different localization of
galectin-3 in the cell is significant for its anti-apoptotic activity.
Induction of apoptosis can translocate galectin-3 to the peri-
nuclear membrane, while nuclear export of galectin-3 is shown
to be involved in anti-apoptotic activity [44]. Therefore, it is
possible that the balance between intracellular and extracellular
galectin-3 with pro-apoptotic or anti-apoptotic functions may be
a critical determinant in the fate of these cells. However, we
conclude that at least in mast cells, exogenous galectin-3 acts as
a powerful inducer of apoptosis.
Galectins have been shown to bind to a wide spectrum of
glycoproteins and bind to different cell surface glycoconjugates in
different cell types. They recognize a group of glycoconjugates
rather than bind to specific receptors. Thus, galectins may engage
a number of cell surface molecules in a given cell type. Indeed, it
has been shown that in Tcells, exogenous galectin-3 and galectin-
1 bind to distinct cell surface glycoprotein receptors to induce
apoptosis [42]. Our data showing that exogenous lactose can
block galectin-3-induced apoptosis support the role of galectin-3
binding to a putative receptor via the CRD. Moreover, we
demonstrate that mast cells express RAGE on their surfaces and
that neutralizing RAGE specifically prevents the galectin-3-
induced apoptosis. Anti-RAGE IgG did not affect TG-induced
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induced apoptosis. Taken together, these data strongly suggest
that RAGE is a galectin-3 receptor that is involved in pro-
apoptotic activity. It is noteworthy that earlier work has suggested
that galectin-3 is localized in the secretory granules of human
mast cells and that these cells may release galectin-3 when
activated to degranulate [45]. Therefore, it is possible that
galectin-3 released into the vicinity of these cells, binds to a
putative receptor on their surfaces or other cell surfaces via the
CRD, thereby triggering the apoptotic signaling pathway.
Mitochondria are now recognized as central gateway
controllers in the cell death pathway and the critical step in the
mitochondrial pathway is increased permeability of the mito-
chondrial outer membrane. The increased permeability triggers
the release of apoptogenic proteins, including cytochrome c
from themitochondrial intermembrane space into the cytoplasm,
which activates the caspase-dependent death pathway. Our data
showing that z-DEVD-fmk, a caspase-3 inhibitor can block
galectin-3-induced apoptosis completely, indicate that a possible
mechanism of galectin-3-induced apoptosis is a rupture of the
mitochondrial integrity. The mitochondrial channel, PTP, in the
inner membrane has been proposed to be responsible for the
increased permeability of the mitochondrial outer membrane,
though this role still remains controversial [28,29]. Although the
molecular identity of the PTP has not yet been resolved, the
adenine nucleotide translocase (ANT) has been proposed for
many years to be one of the components of the PTP. BKA closes
the PTP and inhibits ANT, while, ATR opens the PTP and ANT
[30,31]. Our data clearly demonstrate that the opening of the
PTP is involved in the galectin-3-induced apoptosis. Moreover,
we found that the PTP agonist ATR greatly facilitated galectin-1-
induced apoptosis. The data strongly suggest that galectin-3 but
not galectin-1 alone can induce the PTP opening sufficiently
enough to evoke the permeabilization of the outer mitochondrial
membrane and the activation of the caspase-dependent execu-
tion of cell death.
Another important and novel finding, which appears to be
relevant to the role of the PTP, is that ROS mediate galectin-3-
induced apoptosis. We found that exogenous SOD and DTT
completely protected mast cells from galectin-3-induced apo-
ptosis but not TG-induced apoptosis. This strongly suggests that
extracellular ROS especially O2
U− and thiol oxidation mediate
galectin-3-induced apoptosis. Consistent with this view, galec-
tin-3 specifically induced the production and extracellular
release of O2
U−, which was significantly blocked by lactose and
neutralizing RAGE. Thus, it is possible that galectin-3 binding to
surface counterparts including RAGE via the CRD results in the
production and extracellular release of O2
U−, which mediates pro-
apoptotic activity of galectin-3. ROS generated inside and out-
side the mitochondria are implicated to play a role in the outer
membrane permeability [29].Moreover, ROS can be regarded as
one of the physiological regulators of the PTP open-closed
transitions. It is noteworthy that ANT has three cysteine residues
whose oxidation is critical for the PTP open-closed transitions
[46,47]. Given that the PTP plays an important role in regulating
mitochondrial and intracellular Ca2+ homeostasis [24], it is
conceivable that ROS facilitate the PTP opening via thioloxidation of ANT and impairment of Ca2+ homeostasis, thereby
contributing to cell death. To our interest, it was reported that
galectin-3 exhibited the anti-apoptotic activity in cancer cells by
inhibiting mitochondrial depolarization and damage [48]. These
facts suggest that the effect of galectin-3 on cell death (pro-
apoptotic or anti-apoptotic) andmitochondrial integrity (damage
or protection) may be defined depending on many cellular
parameters including cell type. Further studies on the biochem-
ical and biological consequences of galectin stimulation and the
PTP opening are underway.
In conclusion, we present evidence that exogenous galectin-
3 exhibits pro-apoptotic activity in mast cells by oxidative stress
and mitochondrial permeability transition through binding to
putative surface receptors including RAGE via the CRD. To our
knowledge, this is the first report demonstrating that galectin-3
regulates mast cell death, shedding light on the role of galectins
in mast cell survival.
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